Lonza to support Pionyr Immunotherapeutics' oncology drug development
![](/46/pdcnewsitem/11/15/26/HLN00CPO_Lonza_990x525.jpg)
The CDMO will provide cell line development, process development, drug substance and drug product manufacturing for Pionyr’s monoclonal antibody candidate
Pionyr Immunotherapeutics and Lonza have entered into a collaboration to manufacture Pionyr’s monoclonal antibody candidate intended for oncology indications.
Lonza will provide a gene to IND program tailored to suit the specific requirements of Pionyr’s products. The scope will include cell line development, process development, supply chain simplification and de-risking, as well as drug substance manufacturing at Lonza’s Visp (Switzerland) site, and drug product manufacturing at Stein (Switzerland) to help Pionyr advance their programs into clinical development and testing.
The cell line development to drug product program will begin in Q2 2021. The cGMP batches of drug substance and drug product are expected to be completed early next year.
Developing a high-producing, stable cell line represents a critical path activity for the production of large quantities of therapeutic antibodies. This collaboration will allow Pionyr to take advantage of the Beacon platform, which can screen and monitor thousands of clones at once and in a short time, thereby optimizing and streamlining the cell line construction process.
The collaboration will initially focus on Pionyr’s third program named PY265, which is directed against an undisclosed target. Similar to Pionyr’s PY314 and PY159 programs (targeting TREM2 and TREM1, respectively), this third program is anticipated to be first-in-class and will have a distinct mechanism of action from other myeloid-directed therapeutics currently in development.
![Lonza](https://www.cphi-online.com/c248548th_S-comp248548.jpg)
Related News
-
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance